Morning Radar: (Nasdaq: OPTH) Claims Our Top Watchlist Spot (5 Key Potential Catalysts)

As mental health needs continue to outpace traditional solutions

Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on Behalf of Optimi Health Corp. Morning Radar: (Nasdaq: OPTH) Claims Our Top Watchlist Spot (5 Key Potential Catalysts) *Click Here To Get Our Alerts Faster Via SMS* June 8th Dear Reader, As mental health needs continue to outpace traditional solutions, a new wave of innovation is emerging within the treatment-resistant depression ("TRD") space. With the market projected to reach $3.36Bn by 2031, growing at a steady 7.64% annually, attention is shifting toward novel therapeutic approaches that challenge long-standing limitations. One under-the-radar company is advancing a differentiated strategy focused on addressing gaps in efficacy, accessibility, and patient experience. Its progress reflects broader momentum in this sector, where scientific validation and regulatory pathways are beginning to align, creating conditions for meaningful impact across a large and underserved patient population. And with a low float below 4Mn shares and several recent-term news releases highlight a company on the move, this Nasdaq idea is topping our watchlist Monday: Optimi Health Corp. (Nasdaq: OPTH) Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psych-e-delic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MD-MA and botanical psi-lo-cybin drug products at its GMP-compliant facilities in British Columbia, Canada. And based on multiple potential catalysts, (Nasdaq: OPTH) has hit our radar. Take a look: #1. A Low Float Could Create The Environment For Heightened Volatility. #2. Commercial Production Completed (To Treat TRD In Australia + Clinical Trials In The U.S. And Europe). #3. Australia's Revised Framework Could Accelerate Adoption And Expand Reimbursement Opp's. #4. Diamond Equity Research Puts The OPTH In The Spotlight With An In-Depth Report. #5. The Company Achieves Key Manufacturing Milestone With Its Highest-Purity Natural Extract To Date. But more on those in a second... Optimi Health Corp. produces finished-dose psi-lo-cybin and M-D-M-A capsules for regulated therapeutic use. The Company operates a Health Canada GMP-compliant facility in Princeton, British Columbia, and holds a Drug Establishment Licence authorizing commercial manufacture, packaging, testing, and international export of controlled drug products. Active supply operations began under the Australian Authorized Prescriber Scheme in 2024.  Product is dispensed to patients through authorized clinics for post-traumatic stress disorder and treatment-resistant depression. The Company is structured to scale into additional jurisdictions as regulatory access develops, including the United States upon federal rescheduling. What Makes Optimi Health Different #1. Commercial Today M-D-M-A and psi-lo-cybin capsules in the hands of authorized prescribers in Australia. Revenue recognized since Q2 2024. #2. GMP At The Core Health Canada Drug Establishment Licence. International export authorization. Built to pharmaceutical standards. #3. Direct To Clinic No middlemen. Optimi Health supplies authorized clinics, pharmacies, and clinical trial sponsors directly. #4. Rescheduling-Ready Infrastructure, quality systems, and regulatory posture in place to scale into U.S. therapeutic access as it opens. Positioning Most public psych-e-delic comparables are drug developers — they burn capital through clinical trials and have not yet crossed into revenue-generating supply. Optimi is already a manufacturer and supplier to regulated access programs, with revenue recognized since Q2 2024. The question shifts from "will the asset read out?" to "how fast does regulated access expand, and how defensible is the manufacturing position when it does?" Where Commercial-Stage Psych-e-delic Companies Stand Today The difference between research-stage and commercial-stage, where revenue comes from, and how Optimi fits among the public comparables. The Taxonomy - Where Optimi Sits Market Shape 2 National Commercial Frameworks Australia (TGA Authorized Prescriber Scheme, 2023) and Canada (Special Access Program, 2020) — the only two countries with population-level commercial access to psi-lo-cybin and M-D-M-A in 2026. 100Mn+ TRD Patients Globally WHO data on major depression cited above; ~30–40% of MDD patients meet treatment-resistant criteria. The market is gated by access frameworks and prescribers, not patient demand. 0 FDA-Approved Psych-e-delic Medicines Pre-1985, M-D-M-A was unscheduled; today, no psi-lo-cybin or M-D-M-A product is FDA-approved. Lykos's 2024 NDA was declined; Compass Pathways targets a 2026 NDA submission. Optimi operates a Health Canada GMP-compliant facility in Princeton, British Columbia, authorized for the commercial manufacture, packaging, testing, and international export of controlled drug products. Each lot is produced under a Drug Establishment Licence, tested by HPLC and mass spectrometry, and released by a Qualified Person in accordance with Health Canada GMP requirements. Health Canada Drug Establishment Licence - Issued Health Canada International Export Authorization - Active The Process - Five Steps, Cultivation To Clinic #1. API Synthesis Natural or synthetic psi-lo-cybin; synthetic M-D-M-A HCl. Produced under GMP; tested by HPLC and mass spectrometry. #2. Formulation Finished-dose oral capsules at specified strength. Uniformity and dissolution tested per USP. #3. QP Release Each lot reviewed and released by a Qualified Person. Labeled per Health Canada DEL requirements. #4. Permit Export Under international nar-cotic export permit to authorized importer in destination country. #5. Clinic Dispense Dispensed to patient by authorized prescriber within a regulated therapy program. Optimi Pathways Find Report Sources And More Here: OPTH Website. ----- And as we mentioned above, (Nasdaq: OPTH) has multiple potential catalysts on our radar. Check them out: #1. OPTH Potential Catalyst - A Low Float Could Create The Environment For Heightened Volatility. According to info from the Finviz website, OPTH has a pretty low float. The website reports this profile to have roughly 3.41Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If the company provides positive news during the first half of 2026, could it help provide a breakout spark when paired with this volatility potential? ----- #2. OPTH Potential Catalyst - Commercial Production Completed (To Treat TRD In Australia + Clinical Trials In The U.S. And Europe). Optimi Health Completes Commercial Psi-lo-cybin Production to Address Treatment-Resistant Depression in Australia Optimi's 5mg psi-lo-cybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe VANCOUVER, BC, June 2, 2026 /CNW/ - via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psych-e-delic drug products, today announced the completion of a GMP production run of its 5mg psi-lo-cybin finished drug product. The finished psi-lo-cybin capsules use the same formulation already prescribed to patients in Australia for treatment-resistant depression ("TRD"). The Company has also updated the product's bottling configuration to improve ease of use for prescribers and patients in the Australian market. Additional product from the same production run is earmarked to support upcoming clinical research in the United States and clinical trials in Europe across various indications. ... "Optimi is one of the only companies to take naturally derived psil-o-cybin from biomass to a finished drug product, entirely under one roof and on our own licence," said Dane Stevens, CEO and Co-Founder of Optimi. "What sets Optimi apart is that we serve both sides of this market simultaneously. The same 5mg psi-lo-cybin medicine prescribed in-clinic for treatment-resistant depression today, within a fully regulated framework, is the drug also being studied in clinical trials across a range of indications. We are proud to supply patients today and the researchers shaping what comes next." ... Read the full article here. ----- #3. OPTH Potential Catalyst - Australia's Revised Framework Could Accelerate Adoption And Expand Reimbursement Opp's. Optimi Health (OPTH) Highlights Australia Psych-e-delic Therapy Expansion Following TGA Framework Update LOS ANGELES, CA - May 29, 2026 (NEWMEDIAWIRE) - Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), ..., welcomed final recommendations from Australia's Therapeutic Goods Administration regarding its Authorized Prescriber scheme for psil-o-cybin and M-D-M-A. The updated framework broadens eligible therapy teams, expands treatment settings beyond hospital environments and supports scaling of psych-e-delic-assisted therapy across Australia, where authorized psychiatrists can prescribe Optimi's GMP-compliant M-D-M-A for PTSD and psi-lo-cybin for treatment-resistant depression. The company said the revised framework could accelerate adoption of psych-e-delic-assisted therapy by increasing workforce capacity, particularly in rural and regional areas, while expanding reimbursement opp's across both public and private payers. Optimi also noted that no serious adverse events have been reported under Australia's regulated commercial psych-e-delic treatment program since December 2025, supporting continued expansion of what the company describes as the world's most advanced commercial market for prescribed psil-o-cybin and M-D-M-A therapies. ... Read the full article here. ----- #4. OPTH Potential Catalyst - Diamond Equity Research Puts The OPTH In The Spotlight With An In-Depth Report. Diamond Equity Research Initiates Coverage on Optimi Health Corp. New York, May 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research LLC, an equity research firm with a focus on small capitalization public companies has initiated coverage of Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN). ... The in-depth 40-page initiation report includes detailed information on Optimi Health’s business model, services, industry overview, financials, management profile, and risks. The full research report is available here. ----- #5. OPTH Potential Catalyst - The Company Achieves Key Manufacturing Milestone With Its Highest-Purity Natural Extract To Date. Optimi Health Advances Highest-Purity Natural Psi-lo-cybin Extract to Date The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia's Authorised Prescriber Scheme, where no serious adverse events have been reported as of December 2025 Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psych-e-delic drug products, today announced the completion of a production run of naturally derived psi-lo-cybin extract measuring approximately 6% psi-lo-cybin content, representing the highest-purity botanical psi-lo-cybin extract produced by the Company to date. The milestone reflects sustained gains across Optimi's cultivation program. Drawing on a proprietary library of more than 200 distinct mush-room genetics maintained at the Company's facilities, Optimi has selectively advanced cultivars demonstrating increasingly elevated psi-lo-cybin content. Those cultivation improvements, combined with refinements to the Company's extraction process, have produced a botanical extract substantially more concentrated than prior production cycles while maintaining its naturally derived profile. A portion of the completed extract has been earmarked to support upcoming clinical research programs in Europe, where Optimi is expected to supply GMP-grade finished material into sponsor-led studies. Consistent with the Company's role as a regulated manufacturer rather than a drug-development sponsor, Optimi's contribution is the supply of psi-lo-cybin-containing finished drug products. ... "Higher purity from naturally derived material is a manufacturing achievement," said Dane Stevens, CEO and Co-Founder of Optimi Health. "We have spent years building a cultivation and extraction platform that gets stronger with every cycle. Reaching 6% psi-lo-cybin while maintaining the botanical footprint at scale is exactly the kind of progress we strive for. It strengthens supply for Australian patients, supports clinical research opp's, and expands the development potential of infrastructure we own and operate." Read the full article here. ----- (Nasdaq: OPTH) Recap - 5 Potential Catalysts Triggering Our Radar #1. A Low Float Could Create The Environment For Heightened Volatility. #2. Commercial Production Completed (To Treat TRD In Australia + Clinical Trials In The U.S. And Europe). #3. Australia's Revised Framework Could Accelerate Adoption And Expand Reimbursement Opp's. #4. Diamond Equity Research Puts The OPTH In The Spotlight With An In-Depth Report. #5. The Company Achieves Key Manufacturing Milestone With Its Highest-Purity Natural Extract To Date. ----- We're officially kicking-off coverage on Optimi Health Corp. (Nasdaq: OPTH). Be on the lookout for updates heading your way shortly. Talk soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. OPTIMI HEALTH CORP. (OPTH:US) (OPTI:CA) previously changed their symbols from OPTIMI HEALTH CORP. (OPTHF:US) (OPTI:CA) Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 06/07/2026 and ending on 06/08/2026 to publicly disseminate information about (OPTH:US) (OPTI:CA) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). These Funds were part of the eighty five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (OPTH:US) (OPTI:CA). Please see important disclosure information here: https://fierceinvestor.com/disclosure/opth-gnxij/#details

Fierce Investor | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice